Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Dunn

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
The Lancet. HIV|October 2, 2015
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trialNicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, et al.
Antiviral Therapy|July 21, 2012
Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA)Charles F Gilks, A Sarah Walker, David T Dunn, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 6, 2010
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoringFred Lyagoba, David T Dunn, Deenan Pillay, et al.
BMC Infectious Diseases|October 25, 2018
Protocol, rationale and design of SELPHI: a randomised controlled trial assessing whether offering free HIV self-testing kits via the internet increases the rate of HIV diagnosisMichelle M Gabriel, David T Dunn, Andrew Speakman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 12, 2018
Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic ReconstructionJean L Mbisa, Peter Kirwan, Anna Tostevin, et al.
BMC Infectious Diseases|August 9, 2019
Pilot phase of an internet-based RCT of HIVST targeting MSM and transgender people in England and Wales: advertising strategies and acceptability of the interventionT Charles Witzel, Michelle M Gabriel, Leanne McCabe, et al.
The Journal of Infectious Diseases|November 27, 2009
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus AbacavirNicaise Ndembi, Nicasie Ndembi, Ruth L Goodall, et al.
The Journal of Infectious Diseases|January 27, 2012
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?Mark Gompels, David T Dunn, Andrew Phillips, et al.
JAMA|July 24, 2012
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trialNicholas I Paton, Ruth L Goodall, David T Dunn, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2025
Assessing Whether Providing Regular, Free HIV Self-Testing Kits Reduces the Time to HIV Diagnosis: An Internet-Based, Randomized Controlled Trial in Men Who Have Sex With MenDavid T Dunn, Leanne McCabe, Denise Ward, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
The Lancet. HIV|October 2, 2015
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trialNicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, et al.
Antiviral Therapy|July 21, 2012
Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA)Charles F Gilks, A Sarah Walker, David T Dunn, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 6, 2010
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoringFred Lyagoba, David T Dunn, Deenan Pillay, et al.
BMC Infectious Diseases|October 25, 2018
Protocol, rationale and design of SELPHI: a randomised controlled trial assessing whether offering free HIV self-testing kits via the internet increases the rate of HIV diagnosisMichelle M Gabriel, David T Dunn, Andrew Speakman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 12, 2018
Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic ReconstructionJean L Mbisa, Peter Kirwan, Anna Tostevin, et al.
BMC Infectious Diseases|August 9, 2019
Pilot phase of an internet-based RCT of HIVST targeting MSM and transgender people in England and Wales: advertising strategies and acceptability of the interventionT Charles Witzel, Michelle M Gabriel, Leanne McCabe, et al.
The Journal of Infectious Diseases|November 27, 2009
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus AbacavirNicaise Ndembi, Nicasie Ndembi, Ruth L Goodall, et al.
The Journal of Infectious Diseases|January 27, 2012
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?Mark Gompels, David T Dunn, Andrew Phillips, et al.
JAMA|July 24, 2012
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trialNicholas I Paton, Ruth L Goodall, David T Dunn, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2025
Assessing Whether Providing Regular, Free HIV Self-Testing Kits Reduces the Time to HIV Diagnosis: An Internet-Based, Randomized Controlled Trial in Men Who Have Sex With MenDavid T Dunn, Leanne McCabe, Denise Ward, et al.
Pageof 8